Trial Profile

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirogabalin (Primary)
Indications Neuropathic pain
Focus Registrational; Therapeutic Use
Sponsors Daiichi Sankyo Company

Most Recent Events

31 Jul 2024 According to a Daiichi Sankyo Company media release, in June 2024, the application was approved in China for the use of mirogabalin (DS-5565: (alpha 2 delta) ligand, brand name in Japan: Tarlige) for the treatment of diabetic peripheral neuropathic pain.
28 Feb 2022 Status changed from active, no longer recruiting to completed.
04 Oct 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com